Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 6Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, B-Cell, Marginal Zone 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Waldenstrom Macroglobulinemia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Hairy Cell 1Hodgkin Disease 1Classic Follicular Lymphoma 1Ann Arbor Stage II Mantle Cell Lymphoma 1Anemia, Refractory, with Excess of Blasts 1Anemia 1

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Classic Follicular Lymphoma × CT-P10 × 30 days × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡